CochlearCHEOF +3.55%62 Days Payable is 164.00 as of Dec. 2025, which is 1% below its 10-year median of 165.38. GuruFocus rates CHEOF with a GF Score™ of 62/100 and a GF Value™ of $209.50 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Cochlear ranks better than 80% on this metric.
Cochlear's average Accounts Payable for the
six
months ended in Dec. 2025 was $191 Mil. Cochlear's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $212 Mil.
Hence, Cochlear's Days Payable for the
six
months ended in Dec. 2025 was 164.00.
The historical rank and industry rank for Cochlear's Days Payable or its related term are showing as below:
CHEOF'
s Days Payable Range Over the Past 10 Years
Min: 115 Med: 165.38 Max: 193.29
Current: 165.28
During the past 13 years, Cochlear's highest Days Payable was 193.29. The lowest was 115.00. And the median was 165.38.
CHEOF's Days Payable is ranked better than 80% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs CHEOF: 165.28
Cochlear's Days Payable
declined
from Dec. 2024 (185.08) to Dec. 2025 (164.00).
It may suggest that Cochlearaccelerated paying its suppliers.
Cochlear Days Payable Related Terms
Cochlear Days Payable Historical Data
* Premium members only.
The historical data trend for Cochlear's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cochlear's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Days Payable distribution charts can be found below:
* The bar in red indicates where Cochlear's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cochlear's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (CHEOF) has a Days Payable of 164.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cochlear and its competitors. This is near median its historical median of 165.38. Over the past decade, Cochlear's Days Payable has ranged from 115.00 to 193.29. According to the industry distribution chart, Cochlear ranks #159 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 20%.
Is Cochlear's Days Payable too high?
Cochlear's current Days Payable of 164.00 is near median its 10-year median of 165.38. Over the past 10 years, this metric has ranged from a low of 115.00 to a high of 193.29. The Medical Devices & Instruments industry median Days Payable is 68.07. Cochlear's value of 164.00 is 140.9% above this industry median. Based on the distribution chart, Cochlear ranks #159 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cochlear has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #159 out of 795 companies for Days Payable. This places Cochlear in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Cochlear's value of 164.00 is 140.9% above this benchmark. Historically, Cochlear's own Days Payable has ranged from 115.00 to 193.29 over the past decade. While the company's 10-year median is 165.38 vs. the industry median of 68.07, Cochlear has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current Days Payable of 164.00 is 140.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current Days Payable is 164.00, which is near median its own 10-year median of 165.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOF) is currently considered Significantly Undervalued. The stock's GF Value™ is $209.50, compared to a current price of $82.31 — trading 60.7% below its estimated fair value. The current Days Payable is 164.00, which is near median its 10-year median of 165.38 and 140.9% above the Medical Devices & Instruments industry median of 68.07. Cochlear's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cochlear (CHEOF), the current Days Payable is 164.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (CHEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of $82.31 is trading 60.7% below its estimated GF Value™ of $209.50.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for CHEOF:
Days Payable: 164.00 (near median its 10-year median of 165.38)
GF Value™: $209.50 vs. price of $82.31 (60.7% below fair value)
Industry Position: 140.9% above the Medical Devices & Instruments median (#159 of 795)
No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
62GF Score
Get the complete analysis for CHEOF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHEOF has been successfully added to your 
